Dyspareunia Treatments

Links shared publicly online about this topic

Female sexual dysfunction treatment options | KevinMD.com

kevinmd.com — “Female sexual dysfunction has been reported in up to 40% of women, and described as causing actual distress in approximately 12% of women. Here are some treatments.View full resource at kevinmd.com

  • View Related
  • Share

Most Recently Shared on May 27, 2010 at 7:01 pm By:

JillAllTradesMD JillofAllTrades,MD Family Medicine Doctor, Physician, and Doctor

thx for RT! @Steplor Discussion of diagnosis & treatment options for female sexual dysfunction http://ow.ly/20xJG (via @kevinmd)

2 years ago...

Washington Post Opinion Article Responds To Critics Of Female Sexual Dysfunction Drug

medicalnewstoday.com — “Claims that the development of a drug to treat female sexual dysfunction amounts to disease mongering come down to a delicate judgment call -- that lack of female sexual satisfaction isn't reallView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on June 10, 2010 at 12:37 pm By:

WomensHealth_HL Women's Health Line Health Site

Washington Post Opinion Article Responds To Critics Of Female Sexual Dysfunction Drug http://w.sns.ly/02e45 #womenshealth

2 years ago...

Advisory Panel Says FDA Should Not Approve Drug To Address Female Sexual Dysfunction

medicalnewstoday.com — “On Friday, an FDA advisory panel voted 11-0 against recommending FDA approval of a proposed treatment for hypoactive sexual-desire disorder, which decreases women's sex drive, theView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on June 22, 2010 at 3:44 pm By:

Sexual_HealthOW Sexual_HealthOW OW Health

Advisory Panel Says FDA Should Not Approve Drug To Address Female Sexual Dysfunction: On Friday, an FDA advisory p... http://mnt.to/f/3FbY

2 years ago...

Articles Analyze Debate Surrounding Female Sexual Dysfunction Drug Flibanserin

medicalnewstoday.com — “The Los Angeles Times and New York Times recently examined issues related to the experimental female libido drug flibanserin. On June 18, an FDA advisory panel voted 11-0View full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on June 30, 2010 at 12:59 pm By:

Sexual_HealthOW Sexual_HealthOW OW Health

Articles Analyze Debate Surrounding Female Sexual Dysfunction Drug Flibanserin: The Los Angeles Times and New York... http://mnt.to/f/3FxV

2 years ago...

Phase 3 study of Ophena for treatment of dyspareunia associated with postmenopausal vaginal atrophy - MPR

empr.com — “QuatRx Pharmaceuticals announced positive efficacy results from the second of two patient cohorts in its second Phase 3 study for Ophena (ospemifene tablets) for the treatment of dyspareunia (sexual pain) associated with postmenopausal vulvovaginal atrophy (VVA).View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on September 10, 2009 at 7:25 pm By:

eMPR MPR Medical Publisher

MPR News: Phase 3 study of Ophena for treatment of dyspareunia associated with postmenopausal vaginal a.. http://bit.ly/ma4hs

3 years ago...

Enrollment commences in Palatin's bremelanotide Phase 2b trial for female sexual dysfunction

news-medical.net — “Palatin Technologies, Inc. announced today that enrollment of patients has commenced in Palatin's Phase 2b clinical trial evaluating the efficacy and safety of bremelanotide (previously called PT-141), an on-demand, first-in-class melanocortin agonist being developed for the treatment of female sexual dysfunction (FSD).View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on June 28, 2011 at 9:28 pm By:

Sexual_HealthOW Sexual_HealthOW OW Health

Enrollment commences in Palatin's bremelanotide Phase 2b trial for female sexual dysfunction: Palatin Technologi... http://bit.ly/m5QT6f

11 months ago...

A Viagra for Women? Female Sexual Dysfunction in Spotlight - ABC News

abcnews.go.com — “Attempts to treat female sexual dysfunction with Pfizer's erectile dysfunction drug Viagra have been largely unsuccessful, but a new prototype from the company offers hope for a female-specific treatment for those with Female Sexual Arousal Disorder (FSAD).View full resource at abcnews.go.com

  • View Related
  • Share

Most Recently Shared on April 14, 2010 at 1:23 pm By:

HITpol HealthIT Policy Health News and Health IT

A Viagra for Women? Animal Study Shows Promise: New research sheds light on how to treat female sexual dysfuncti... http://bit.ly/9JJ6cy

2 years ago...

International Journal of Impotence Research - Motivations for seeking treatment for ED: the woman's perspective

nature.com — “International Journal of Impotence Research: The Journal of Sexual Medicine is a print and online publication dedicated to providing the latest research in the field of sexual medicine including male and female sexual dysfunction as it relates to diabetes, cardiology, endocrinology, and primary care medicineView full resource at nature.com

  • View Related
  • Share

Most Recently Shared on March 29, 2011 at 8:40 pm By:

Hlth_Literacy Health Literacy Medical School

#Motivations for seeking treatment for Erectile Dysfunction: the woman's perspective http://ht.ly/4hY0T

1 year ago...

International Journal of Impotence Research - Safety and efficacy of tamsulosin in the treatment of painful ejaculation: a randomized, double-blind, placebo-controlled study

nature.com — “International Journal of Impotence Research: The Journal of Sexual Medicine is a print and online publication dedicated to providing the latest research in the field of sexual medicine including male and female sexual dysfunction as it relates to diabetes, cardiology, endocrinology, and primary care medicineView full resource at nature.com

  • View Related
  • Share

Most Recently Shared on April 12, 2011 at 3:00 am By:

Hlth_Literacy Health Literacy Medical School

Treatment of painful #ejaculation - Safety & efficacy of tamsulosin http://ht.ly/4wUa1

1 year ago...

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

news-medical.net — “Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on August 17, 2010 at 4:56 pm By:

Sexual_HealthOW Sexual_HealthOW OW Health

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction: Palatin Technologies, In... http://bit.ly/a6mf0H

2 years ago...

BioSante Pharmaceuticals Completes Enrollment In LibiGel(R) Phase III Efficacy Trial - QualityPoint Technologies

qualitypointtech.net — “BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced that enrollment of subjects in the first of two pivotal Phase III LibiGel (testosterone gel) safety and efficacy trials has been completed. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved producView full resource at qualitypointtech.net

  • View Related
  • Share

Most Recently Shared on February 27, 2011 at 8:00 pm By:

MedicalFeed MedicalFeed Health News Feed

BioSante Pharmaceuticals Completes Enrollment In LibiGel(R) Phase III Efficacy Trial: BioSante Pharmaceuticals, In... http://bit.ly/gAr0JQ

1 year ago...

BioSante Pharmaceuticals Reaches Key LibiGel(R) Safety Study Enrollment Target

medicalnewstoday.com — “BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced enrollment of the 2,500th woman in the LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. This important enView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on October 19, 2010 at 3:37 pm By:

WomensHealth_HL Women's Health Line Health Site

BioSante Pharmaceuticals Reaches Key LibiGel(R) Safety Study Enrollment Target http://sns.ly/iAU52 #womenshealth

2 years ago...

Enrollment complete in BioSante's LibiGel Phase III cardiovascular and breast cancer safety study

news-medical.net — “BioSante Pharmaceuticals, Inc., today announced completion of enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on May 31, 2011 at 5:09 pm By:

Sexual_HealthOW Sexual_HealthOW OW Health

Enrollment complete in BioSante's LibiGel Phase III cardiovascular and breast cancer safety study: BioSante Phar... http://bit.ly/lLO03h

12 months ago...

The Top 3 resources shared on this topic. More resources.

Key stats and trends about this topic

Featuring the top 3 experts for this topic

Advertisement

Share via Email

Share this WisdomCard with others by embedding on your site or blog.

300x260

425x300

560x390